Rossella Medori

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
    Rossella Medori
    Janssen Cilag EMEA, Neuss, Germany
    Biol Psychiatry 63:981-9. 2008
  2. ncbi Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable
    Rossella Medori
    Janssen Cilag, Medical Affairs EMEA, Beerse, Belgium
    Eur Neuropsychopharmacol 16:233-40. 2006
  3. ncbi Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study
    Robin Emsley
    University of Stellenbosch, Tygerberg, Cape Town, South Africa
    J Clin Psychopharmacol 28:210-3. 2008
  4. ncbi Concordance of patient and clinical ratings of symptom severity and change of psychotic illness
    Jonathan Rabinowitz
    Schizophr Res 100:359-60. 2008
  5. ncbi Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients
    Werner Kissling
    Klinikum rechts der Isar, Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Munchen, Germany
    Hum Psychopharmacol 22:505-13. 2007
  6. ncbi Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone
    Max Schmauss
    Department of Psychiatry, Bezirkskrankenhaus Augsburg, Augsburg, Germany
    Int Clin Psychopharmacol 22:85-92. 2007
  7. ncbi Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates
    Robin Emsley
    University of Stellenbosch, Tygerberg, Cape Town, South Africa
    Schizophr Res 89:129-39. 2007
  8. ncbi [Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD]
    Steffen Heger
    ,
    Z Kinder Jugendpsychiatr Psychother 34:257-65. 2006
  9. ncbi Time course for antipsychotic treatment response in first-episode schizophrenia
    Robin Emsley
    Department of Social Work, Bar Ilan University, Ramat Gan, Israel
    Am J Psychiatry 163:743-5. 2006
  10. ncbi Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
    Hans Jurgen Moller
    Department of Psychiatry, University of Munich, Germany
    Int Clin Psychopharmacol 20:121-30. 2005

Collaborators

Detail Information

Publications13

  1. ncbi A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
    Rossella Medori
    Janssen Cilag EMEA, Neuss, Germany
    Biol Psychiatry 63:981-9. 2008
    ..There is increasing recognition of attention-deficit/hyperactivity disorder (ADHD) in adults and the need to evaluate efficacy and safety of methylphenidate treatment in these patients...
  2. ncbi Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable
    Rossella Medori
    Janssen Cilag, Medical Affairs EMEA, Beerse, Belgium
    Eur Neuropsychopharmacol 16:233-40. 2006
    ..m. every 2 weeks. The constant and slow release of the long-acting formulation leads to less fluctuation in plasma levels and to a D(2)-like receptor occupancy which is below the threshold for EPS...
  3. ncbi Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study
    Robin Emsley
    University of Stellenbosch, Tygerberg, Cape Town, South Africa
    J Clin Psychopharmacol 28:210-3. 2008
    ..5 mg for 30%, and 50 mg for 16%. This preliminary study suggests that RLAI was overall well tolerated and appears to be effective in recent-onset psychosis. Further investigation is warranted...
  4. ncbi Concordance of patient and clinical ratings of symptom severity and change of psychotic illness
    Jonathan Rabinowitz
    Schizophr Res 100:359-60. 2008
  5. ncbi Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients
    Werner Kissling
    Klinikum rechts der Isar, Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Munchen, Germany
    Hum Psychopharmacol 22:505-13. 2007
    ..This post-hoc analysis supports that RLAI is well tolerated and safe in elderly patients with psychotic illnesses switched from stable antipsychotic regimens, and suggests possible efficacy, although inferences are limited...
  6. ncbi Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone
    Max Schmauss
    Department of Psychiatry, Bezirkskrankenhaus Augsburg, Augsburg, Germany
    Int Clin Psychopharmacol 22:85-92. 2007
    ..001). These results indicate that further improvement in symptom control can be seen after a change to risperidone long-acting injectable in clinically stable patients previously treated with oral risperidone...
  7. ncbi Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates
    Robin Emsley
    University of Stellenbosch, Tygerberg, Cape Town, South Africa
    Schizophr Res 89:129-39. 2007
    ..Recently, the "Remission in Schizophrenia Working Group" proposed remission criteria consisting of a reduction to mild levels on key symptoms for at least 6 months...
  8. ncbi [Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD]
    Steffen Heger
    ,
    Z Kinder Jugendpsychiatr Psychother 34:257-65. 2006
    ..In a school setting, the efficacy of OROS-MPH was comparable to that of IR-MPH...
  9. ncbi Time course for antipsychotic treatment response in first-episode schizophrenia
    Robin Emsley
    Department of Social Work, Bar Ilan University, Ramat Gan, Israel
    Am J Psychiatry 163:743-5. 2006
    ..0%, 44.8%, and 27.5% of patients. CONCLUSIONS: Time to antipsychotic response varied widely, suggesting that, in first-episode schizophrenia, longer treatment trials may be necessary...
  10. ncbi Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
    Hans Jurgen Moller
    Department of Psychiatry, University of Munich, Germany
    Int Clin Psychopharmacol 20:121-30. 2005
    ..Direct initiation of RLAI was effective and well tolerated. RLAI provides an advancement in the treatment options available for a wide range of patients requiring long-term antipsychotic therapy...
  11. ncbi Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis
    Joseph Lejeune
    CHR Citadelle, , Belgium
    Int Clin Psychopharmacol 19:259-69. 2004
    ..m. conventional neuroleptic treatment with or without lorazepam. Oral risperidone plus lorazepam rapidly reduces symptoms, including aggression, and causes fewer EPS...
  12. ncbi Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies
    Glenn W Currier
    University of Rochester Medical Center, Rochester, New York, 14642, USA
    J Psychiatr Pract 12:30-40. 2006
    ..A synthesis of data from individual clinical trials, meta-analyses, review articles, and expert consensus recommendations is used to develop a working clinical algorithm for the acute management of aggression and agitation...
  13. ncbi [Tardive dyskinesia: pergolid, a possible therapeutic option]
    Alexander Diehl
    Zentralinstitut fur Seelische Gesundheit, Mannheim, Germany
    Psychiatr Prax 30:333-7. 2003
    ..Low-dose pergolide should activate presynaptic auto receptors, decrease dopamintransmission and reduce tardive dyskinesia...